INOTREM
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received funding from the Crohn’s & Colitis Foundation’s IBD Ventures under a program to accelerate research and development that aim to improve the quality of life for patients with IBD. The funding will support the development of a new therapeutic approach in IBD focusing on the TREM-1 pathway.
The funding follows a R&D collaboration between Inotrem, and the Crohn’s & Colitis Foundation announced in April 2022. The R&D collaboration seeks to pave the way of a personalized medicine approach in IBD patients based on TREM-1. Under the terms of the agreement, Inotrem has access to data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. Lasting over 18 months, the project will be a cornerstone in the design of Inotrem’s first-in-human clinical study with INO-02.
There are today 10 million people worldwide suffering from IBD, and the need for new therapeutic options remains very strong. Approximately 30% of patients are unresponsive to existing therapies and even among the initial responders, in up to 10% the drugs lose efficacy over time. For a decade, Inotrem has been elucidating the biology of TREM-1 as a regulator of the immune response in both acute as well as chronic inflammatory diseases. TREM-1 is a potential important contributor to IBD pathophysiology and targeting this pathway may offer a new treatment option for IBD patients with immune dysregulation.
“We are grateful for the support of such a well-respected organization as The Crohn’s & Colitis Foundation. This funding will help us to expand our patented technology platform centered around the TREM-1 pathway and dedicated to developing new therapies for chronic inflammatory syndromes next to our existing modalities for acute diseases,” indicates Sven Zimmermann, CEO of Inotrem.
“Beyond the financial support, this is a strong recognition of Inotrem’s scientific leadership regarding the role of the TREM-1 pathway in inflammatory processes as well as our robust therapeutic approaches targeting that biological target,” says Marc Derive, Chief Scientific Officer and Cofounder of Inotrem.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sebastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
About the Crohn’s & Colitis Foundation
The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD. The Foundation’s work is dramatically accelerating the research process through investment in research initiatives, while also providing extensive educational and support resources for patients and their families, medical professionals, and the public. For more information, visit crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Amid Global Volatility10.11.2025 17:10:00 CET | Press release
International travel projected to exceed 2 billion arrivals by 2030, despite global economic and geopolitical uncertaintyStrategic investment in infrastructure, policy, and accessibility key to unlocking continued growth TOURISE, in collaboration with Oxford Economics, has released a new white paper titled “Growth Amid Uncertainty: Opportunities and Risks on the Road to 2 Billion Global Travellers,” unveiled during the inaugural TOURISE Summit. The publication presents key opportunities and risks that the industry will face in coming years as well as a framework to guide policymakers, destination leaders, and industry stakeholders in strengthening the tourism sector’s capacity to withstand global disruptions and foster long-term sustainability and resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110254503/en/ TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Ami
Altman Solon Selects Mindbreeze to Power Knowledge Management and Collaboration Across the Organization10.11.2025 16:01:00 CET | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Altman Solon, the world’s largest strategy consulting firm focused exclusively on telecommunications, media, and technology (TMT), has purchased Mindbreeze InSpire. The collaboration began in July 2025 with a trial of the Mindbreeze Insight Workplace, designed to unify Altman Solon’s SharePoint and web-based data sources into a single point of entry for organizational knowledge. Before partnering with Mindbreeze, Altman Solon sought to enhance how its global teams accessed and shared knowledge across systems, a challenge common among consulting firms with vast, fast-growing data ecosystems. The company had built a strong foundation in SharePoint for managing structured project data, but its native search capabilities limited visibility across platforms. Project information was distributed across several secure repositories, making it difficult to form a single, holistic view of our co
NIQ to Present at 2025 J.P. Morgan Ultimate Services Investor Conference10.11.2025 16:00:00 CET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or "NIQ"), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 18, 2025 at 10:20 am ET. A live webcast of the presentation will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delive
Decagon Announces Commercial Pilot with Deutsche Telekom and Strategic Investment from T.Capital to Fuel Enterprise Growth10.11.2025 16:00:00 CET | Press release
WEB SUMMIT 2025 – Decagon, the leader in conversational AI agents for concierge customer experiences, today announced a commercial pilot with global telecommunications provider Deutsche Telekom, as well as a strategic investment from T.Capital, the corporate venture arm of Deutsche Telekom. Deutsche Telekom is the world’s largest telecommunications provider by revenue and serves hundreds of millions of mobile customers across the globe. T.Capital provides early- and late-stage strategic capital to companies that have synergies with parent Deutsche Telekom. “Decagon’s powerful AI is helping businesses deliver an exceptional customer experience,” said Jonathan Abrahamson, Chief Product & Digital Officer at Deutsche Telekom. “The company's innovative approach fits perfectly to our own vision to elevate customer experiences through technology, and we look forward to both our commercial pilot and joining the roster of top-flight investors fueling the company’s impressive product velocity an
Dawex and Innovalia Group Join Forces to Accelerate the Deployment of Data Exchange Solutions in Spain10.11.2025 15:07:00 CET | Press release
Dawex, the leader in data exchange solutions, and Innovalia Group, a strategic group of technology companies specializing in digital transformation solutions, have signed a strategic collaboration agreement to drive the development of secure and sovereign data spaces in the Spanish market through a comprehensive range of products and services. The collaboration brings together two strong and complementary areas of expertise: Dawex’s technological leadership in Data Exchange and the Innovalia Group’s extensive knowledge of the Spanish industrial sector. Dawex and the Innovalia Group are joining forces to offer joint value propositions to large companies, SMEs and public entities, interested in deploying their own digital ecosystems and secure, trusted data spaces. Dawex brings its extensive technology, business and regulatory expertise in creating secure and trusted data ecosystems, such as Corporate Data Hubs, Data Marketplaces and Industry Data Spaces, to create data spaces and improv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom